Acute Myeloid Leukaemia News and Research RSS Feed - Acute Myeloid Leukaemia News and Research

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Novel cell sorting enhancement to MoFlo Astrios platform to be introduced by Beckman Coulter Life Sciences at CYTO 2013

Novel cell sorting enhancement to MoFlo Astrios platform to be introduced by Beckman Coulter Life Sciences at CYTO 2013

... [More]
Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC

Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC

Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). [More]
Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy. [More]
Boehringer Ingelheim announces new data from volasertib Phase I/II leukemia study

Boehringer Ingelheim announces new data from volasertib Phase I/II leukemia study

Boehringer Ingelheim today announced that new data evaluating volasertib, an investigational polo-like kinase (Plk) inhibitor, will be presented at the 54th American Society of Hematology (ASH) annual meeting taking place December 8-11 in Atlanta, Ga. [More]
EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

EC approves Janssen’s DACOGEN for treatment of de novo acute myeloid leukaemia

Janssen-Cilag International NV announced today that the European Commission has approved the marketing authorisation for DACOGEN(decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organisation (WHO) classification, who are not candidates for standard induction chemotherapy. [More]
Boehringer Ingelheim files MAA with EMA for afatinib approval

Boehringer Ingelheim files MAA with EMA for afatinib approval

Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission. [More]
Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Janssen-Cilag International NV announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of DACOGEN (decitabine) for Injection. [More]
The key to treating AML may lie within FTL3 gene mutations

The key to treating AML may lie within FTL3 gene mutations

The key to treating one of the most common types of human leukemia may lie within mutations in a gene called FLT3, according to new research led by physician-scientists at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. [More]

Scientists identify potential drug target for mixed lineage leukaemia

Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia - a cancer with limited treatment options and relatively poor survival, according to research published in Cancer Cell today. [More]
Antidepressant could help the workings of anticancer drug used in leukemia

Antidepressant could help the workings of anticancer drug used in leukemia

The study by scientists at the Institute of Cancer Research found that tranylcypromine (TCP) – which can be used to treat psychotic depressive states - can make cancer cells vulnerable to the effects of a vitamin A-derivative drug called ATRA. [More]

Cancer Research UK opens first AT9283 trial to treat childhood leukaemia

Cancer Research UK's Drug Development Office has opened the first trial of a new type of drug to treat children aged from six months to 18 years with acute leukaemia, who are no longer responding to treatment. [More]

'Pro-survival' protein inhibitors may improve outlook for AML patients

Melbourne researchers have discovered that acute myeloid leukaemia (AML), an aggressive blood cancer with poor prognosis, may be susceptible to medications that target a protein called Mcl-1. [More]

Researchers identify genetic conspirators underlying acute myeloid leukaemia

Researchers have described how the most common gene mutation found in acute myeloid leukaemia starts the process of cancer development and how it can cooperate with a well-defined group of other mutations to cause full-blown leukaemia. [More]

Study: Antibody-directed chemotherapy may be effective for majority of younger AML sufferers

Antibody-directed chemotherapy offers improved survival to particular sub-groups of leukaemia sufferers, a Cardiff University-led study has found. [More]

PanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies to kick off in Lund, Sweden

By learning more about these late effects of treatment, the health care services can, on the one hand, improve and reduce the intensity of the treatment, and, on the other hand, find appropriate ways to care for those suffering from side-effects of the treatment in adolescence and adulthood. [More]
Scientists to commence new DNA vaccine trial for use in patients with leukemia

Scientists to commence new DNA vaccine trial for use in patients with leukemia

A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK. The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer. [More]
New clue in leukemia mystery

New clue in leukemia mystery

There is new hope for people with acute myelogenous leukemia (AML), a fast-growing cancer of the blood and bone marrow. Research led by Weill Cornell Medical College and published today in the online edition of the journal Cancer Cell reveals a surprising and unexpected cancer-causing mechanism. The investigators discovered that newly identified mutant enzymes in AML create a chemical poison to cause leukemia. Their findings should prove useful in treating patients by providing a molecular target against which to develop new drugs against one subset of AML as well as other cancers. [More]
Scientists find that protease HtrA2 can "clean" cells of oncogene WT1

Scientists find that protease HtrA2 can "clean" cells of oncogene WT1

Dr Jorg Hartkamp and Dr Stefan Roberts have found that the protease HtrA2 can "clean" cells of the oncogene WT1, which is found at high levels in many leukaemias and solid cancers such as breast and lung cancer. [More]
Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

4SC AG, a drug discovery and development company, today announced the start of dosing in a First-in-Man Phase I study in healthy volunteers evaluating 4SC-203, a novel multi-target kinase inhibitor, with particular specificity against selected kinases, including FMS-like tyrosine kinase 3 (FLT3), FLT3 mutants and vascular endothelial growth factor receptors (VEGF-R). [More]

Scientists identify new potential drug for treating acute myeloid leukaemia

EUREKA project E! 3172 NKSTIM has produced a new potential drug to stimulate cancer patients' own 'natural killer' cells to attack and eliminate cancer cells; currently undergoing clinical testing in patients with leukaemia or myeloma. [More]